A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients with High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid Tumors

NCT #
Condition(s)
Lymphoma, Solid Tumor
Molecular Target(s)
MDM2
Drug Classification(s)
Molecular Targeted Therapy
Agents(s)
KT-253
Phase(s)
I

Mechanism of Action

KT-253 is an MDM2 degrader

Purpose

  • How much of the study drug can be given with an acceptable level of side effects
  • The effects of the study drug (good and bad)
  • How much of the study drug is absorbed into the blood and how fast it is removed
  • If research tests can be used in the future to predict who will benefit from KT-253
  • How the study drug is acting on your body

Location

Mary Crowley Cancer Research - Medical City Dallas

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

7777 Forest Lane,
Building C-707
Dallas, TX 75230

972.566.3000